On May 11, 2022 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), reported the grant of patent application no. 15/753,882 entitled "USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS" by the US Patent Office (Press release, Oncotelic, MAY 11, 2022, View Source [SID1234614233]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The claims of the patent are directed to a pharmaceutical composition for producing an anti-tumor effect in a subject suffering from cancer or a tumor, comprising a Vascular Disrupting Agent (VDA) comprising a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-i antibody, a PD-Li antibody, and a PD-L2 antibody in amounts effective therefore in a pharmaceutical carrier, where in the VDA is combretastatin Al diphosphate (CAl P) or combretastatin A4 phosphate (CA4P) or others.

"With the completion of the Joint Venture with Dragon Overseas Capital Limited for OT-101, we are now in the position to strengthen Mateon’s legacy assets including CA4P and Oxi4503," said Dr. Vuong Trieu, CEO and Chairman. "Given our team experience in VDA space as well as Abraxane and Cynviloq, we feel that we can successfully redeploy CA4P and Oxi4503 for the treatment of difficult to treat cancers either alone or in combination with Pembrolizumab/Keytruda."